95-5-49
mAbexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 12, 1996 (NCT00001507)
Timeline
1990s
- Jan 1, 1996
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- T-cell surface antigen CD2INHIBITOR
CD2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- 95-5-49
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00001507 | Phase 1 | Jul 12, 1996 | National Cancer Institute (NCI) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 1996 |
1 organizations
Page 1 / 1